GlassScriptPhysician profile
Paul Urban
NPI 1508961756
$6,513.89
in general payments reported to CMS, 2019-2025
36 companies · $1,136 in 2025
The $1,136 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $987 · 2020: $443 · 2021: $918 · 2022: $678 · 2023: $903 · 2024: $1,450 · 2025: $1,136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,488.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,488.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,023.54 | 2019-2025 | |
| Amgen INC. | $641.61 | 2019-2025 | Repatha, Repatha |
| Abbott Laboratories | $569.48 | 2021-2025 | Aveir, Jot Dx, Navitor |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $438.90 | 2019-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $429.16 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $391.14 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $289.37 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $283.59 | 2019-2024 | Farxiga, Brilinta |
| Philips North America LLC | $266.53 | 2020-2025 | Ecc Solutions, (Cm9) Amb Mon & Diag Und |
| Biotronik INC. | $246.82 | 2021-2025 | Biomonitor, Acticor 7 Vr-T Dx, Renamic Neo |
| Angiodynamics, INC. | $245.50 | 2023-2025 | Auryon Laser System 100-120 Vac |
| Medtronic, INC. | $208.40 | 2021-2025 | Onyx Frontier |
| Kestra Medical Technology Services, INC. | $178.29 | 2024-2025 | Assure Wcd |
| Merck Sharp & Dohme LLC | $138.98 | 2021-2024 | Verquvo |
| Boston Scientific Corporation | $136.59 | 2021-2025 | Watchman Flx, Vigilant X4 Crt-D, General - Crm_crm |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $110.38 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $94.83 | 2019-2025 | Camzyos, Eliquis |
| Esperion Therapeutics, INC. | $91.86 | 2021-2025 | Nexletol |
| Lexicon Pharmaceuticals, INC. | $87.22 | 2023-2024 | Inpefa |
| Atricure, INC. | $83.04 | 2023-2024 | |
| Alnylam Pharmaceuticals INC. | $78.31 | 2021-2025 | Onpattro |
| Impulse Dynamics (USA) INC. | $65.12 | 2022 | |
| Cook Medical LLC | $64.97 | 2025 | Zilver Ptx, Icast Covered Stent System, 6mmx22mmx120cm, Advance |
| Medtronic Vascular, INC. | $59.12 | 2020 | |
| Amarin Pharma, INC. | $52.25 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $44.55 | 2019-2024 | Evkeeza |
| Abiomed | $39.39 | 2025 | |
| Gilead Sciences, INC. | $32.33 | 2019 | |
| Akcea Therapeutics, INC. | $22.58 | 2020 | |
| Inari Medical, INC. | $22.06 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Allergan, INC. | $21.58 | 2019 | |
| Braemar Manufacturing, LLC | $18.91 | 2019 | |
| Arbor Pharmaceuticals, INC. | $15.06 | 2019 | |
| Bardy Diagnostics, INC. | $12.00 | 2022 | |
| Cardiovascular Systems INC. | $10.43 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,272,016.02 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Urban listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.